Healthcare Industry News: Horizon Pharma
News Release - March 5, 2014
Horizon Pharma Names Robert F. Carey Executive Vice President and Chief Business Officer
DEEFIELD, IL--(Healthcare Sales & Marketing Network) - Horizon Pharma, Inc. (NASDAQ: HZNP) today announced the appointment of Robert F. Carey as executive vice president and chief business officer, bringing a broad base of healthcare investment banking experience. Mr. Carey has assisted biotech and specialty pharma companies raise more than $10 billion in initial public offerings, follow-on offerings, debt offerings and private placements. He has also served as a financial advisor on mergers, acquisitions and strategic alliance transactions with a total deal value of more than $3 billion.Prior to joining Horizon, Mr. Carey spent more than 11 years as managing director and head of the life sciences investment banking group at JMP Securities LLC, a full-service investment bank. Prior to JMP, Mr. Carey was a managing director in the healthcare groups at Dresdner Kleinwort Wasserstein and Vector Securities. Mr. Carey also has held roles at Red Hen Bread, InStadium, Shearson Lehman Hutton and Ernst & Whinney.
Mr. Carey holds a bachelor's degree from the University of Notre Dame.
About Horizon Pharma
Horizon Pharma, Inc. is a commercial stage, specialty pharmaceutical company that markets DUEXIS®, RAYOS®/LODOTRA® and VIMOVO®, which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The Company's strategy is to develop, acquire or in-license additional innovative medicines where it can execute a targeted commercial approach among specific target physicians such as primary care physicians, orthopedic surgeons, and rheumatologists, while taking advantage of its commercial strengths and the infrastructure the Company has put in place. For more information, please visit www.horizonpharma.com.
Source: Horizon Pharma
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
